Segurança da tibolona como terapia de reposição hormonal em mulheres menopáusicas: uma revisão de escopo
DOI:
https://doi.org/10.59464/2359-4632.2024.3533Palabras clave:
Menopausa, Pessoa de Meia-Idade, Terapia de Reposição Hormonal., Segurança do PacienteResumen
Objetivo: evaluar la seguridad de la tibolona como terapia de reemplazo hormonal en mujeres menopáusicas. Métodos: se trata de una revisión de alcance, desarrollada en las bases de datos Pubmed, Web of Science y Scopus. Se consideraron estudios de cohorte, ensayos clínicos, estudios observacionales y revisiones que respondieran a la siguiente pregunta orientadora: ¿Cuáles son las evidencias disponibles sobre la seguridad de la tibolona como terapia de reemplazo hormonal en mujeres menopáusicas? Los estudios debían estar disponibles en texto completo y de forma gratuita, y haber sido publicados entre 2014 y agosto de 2024. Los resultados primarios de interés incluyeron datos sobre la seguridad del uso de la tibolona, como el riesgo de cáncer de mama, cáncer endometrial, eventos cardiovasculares, efectos adversos e impacto en la salud ósea. Tras el cruce de descriptores controlados, se encontraron 323 estudios, de los cuales se seleccionaron 28. Resultados: la mayoría de los estudios se publicaron en el año 2024 (21,43%), abordando temas sobre terapia hormonal y la aparición de cáncer. La tibolona demostró ser una opción relativamente segura, ya que no aumenta el riesgo de cáncer de mama o de ovario en mujeres menopáusicas y posmenopáusicas. Conclusión: la tibolona tiene buena eficacia y seguridad en la terapia de reemplazo hormonal en mujeres en menopausia y posmenopáusicas, aunque su indicación debe evaluarse cuidadosamente.
Citas
Davis SR, Pinkerton J, Santoro N, Simoncini T. Menopause-Biology, consequences, supportive care, and therapeutic options. Cell. 2023;186(19):4038-4058. doi: https://doi.org/10.1016/j.cell.2023.08.016
Fooladi E, Bell RJ, Masoumi M, Azizi M, Atarod Z, Davis SR. Bothersome menopausal symptoms amongst postmenopausal Iranian women. Climacteric. 2018;21(6):586-593. doi: https://doi.org/10.1080/13697137.2018.1493452
Islam RM, Bell RJ, Rizvi F, Davis SR. Vasomotor symptoms in women in Asia appear comparable with women in Western countries: a systematic review. Menopause. 2017;24(11):1313-1322. doi: https://doi.org/10.1097/GME.0000000000000896
Yang Y, Arnot M, Mace R. Current ecology, not ancestral dispersal patterns, influences menopause symptom severity. Ecol Evol. 2019;9(22):12503-12514. doi: https://doi.org/10.1002/ece3.5705
Tepper PG, Brooks MM, Randolph JF Jr, Crawford SL, El Khoudary SR, Gold EB, Lasley BL, Jones B, Joffe H, Hess R, Avis NE, Harlow S, McConnell DS, Bromberger JT, Zheng H, Ruppert K, Thurston RC. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause. 2016;23(10):1067-74. doi: https://doi.org/10.1097/GME.0000000000000676
Baker FC. Optimizing sleep across the menopausal transition. Climacteric. 2023 Jun;26(3):198-205. doi: https://doi.org/10.1080/13697137.2023.2173569
Hachul H, Castro LS, Bezerra AG, et al. Hot flashes, insomnia, and the reproductive stages: a cross-sectional observation of women from the EPISONO study. J Clin Sleep Med. 2021;17(11):2257–2267. doi: https://doi.org/10.5664/jcsm.9432
Madsen TE, Sobel T, Negash S, Shrout Allen T, Stefanick ML, Manson JE, Allison M. A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause. Int J Womens Health. 2023 25; 15:825-836. doi: https://doi.org/10.2147/IJWH.S379808
Grandi G, Caroli M, Cortesi L, et al. Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which? Expert Opin Drug Saf. 2020;19(8):1025-1030. doi: https://doi.org/10.1080/14740338.2020.1791818
Poggio F, Del Mastro L, Bruzzone M, Ceppi M, Razeti MG, Fregatti P, Ruelle T, Pronzato P, Massarotti C, Franzoi MA, Lambertini M, Tagliamento M. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;191(2):269-275. doi: https://doi.org/10.1007/s10549-021-06436-9
Goodwin PJ. Tibolone: the risk is too high. Lancet Oncol. 2009;10(2):103-4. doi: https://doi.org/10.1016/S1470-2045(09)70009-9
Ugras SK, Layeequr Rahman R. Hormone replacement therapy after breast cancer: Yes, No or maybe? Mol Cell Endocrinol. 2021;525:111180. doi: https://doi.org/10.1016/j.mce.2021.111180
Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors - Review of the Literature. Pathol Oncol Res. 2020;26(1):63-78. doi: https://doi.org/10.1007/s12253-018-00569-x
Yuk JH, Noh JH, Kim MH, Han GH, Kim J, Cho H, Gwak G, Lee Y. Relationship between menopausal hormone therapy and colorectal cancer: a cohort study utilizing the health insurance database in South Korea (HISK)-II. Menopause. 2024 Aug 1;31(8):686-692. doi: https://doi.org/10.1097/GME.0000000000002376
Yuk JS. Relationship between menopausal hormone therapy and breast cancer: A nationwide population-based cohort study. Int J Gynaecol Obstet. 2024 Aug;166(2):735-744. doi: https://doi.org/10.1002/ijgo.15461
Yuk JS, Kim GS, Byun YS, Yang SW, Kim MH, Yoon SH, Seo YS, Kim BG. Effect of menopausal hormonal therapy on cardiovascular risks in Korean postmenopausal women: A nationwide cohort study. BJOG. 2024 Aug;131(9):1306-1317. doi: https://doi.org/10.1111/1471-0528.17803
Choi E, Lee JK, Baek JK, Chung Y, Kim H, Yun BH, Seo SK. Hormone replacement therapy and breast cancer incidence in Korean women. Maturitas. 2024 May;183:107946. doi: https://doi.org/10.1016/j.maturitas.2024.107946
Baek JK, Kim HY, Kang MJ, Choi EA, Lee JK, Kim EH, Seo SK. Hormone replacement therapy and myocardial infarction and stroke in postmenopausal Korean women. Climacteric. 2024 Aug;27(4):406-412. doi: https://doi.org/10.1080/13697137.2024.2354728
Yuk JS, Kim T, Cho H, Gwak G. Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea-based cohort study. Eur J Endocrinol. 2024 Jan 3;190(1):1-11. doi: https://doi.org/10.1093/ejendo/lvad168
Kim H, Kang MJ, Baek JK, Lee JK, Choi EA, Yun BH, Kim EH, Seo SK. Relationship between menopausal hormone therapy and incidence of fractures in postmenopausal women. Climacteric. 2024 Apr;27(2):165-170. doi: https://doi.org/10.1080/13697137.2023.2273528
Hsiao SM, Chang SR. Effect of tibolone versus hormone replacement therapy on lower urinary tract symptoms and sexual function. J Formos Med Assoc. 2024 Jun;123(6):710-715. doi: https://doi.org/10.1016/j.jfma.2023.12.007
Yuk JS, Park JY. Menopausal hormone therapy increases the risk of gallstones: Health Insurance Database in South Korea (HISK)-based cohort study. PLoS One. 2023 Dec 4;18(12):e0294356. doi: https://doi.org/10.1371/journal.pone.0294356
Yuk JS, Lee SK, Uh JA, Seo YS, Kim M, Kim MS. Skin cancer risk of menopausal hormone therapy in a Korean cohort. Sci Rep. 2023 Jun 29;13(1):10572. doi: https://doi.org/10.1038/s41598-023-37687-9
Yuk JS. Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea-based cohort study. Int J Gynaecol Obstet. 2023 Aug;162(2):502-513. doi: https://doi.org/10.1002/ijgo.14753
Yuk JS, Kim JM. Menopausal hormone therapy and the risk of type 2 diabetes mellitus: Health Insurance Database in South Korea-based retrospective cohort study. Menopause. 2023 May 1;30(5):497-505. doi: https://doi.org/10.1097/GME.0000000000002170
Yuk JS, Kim M. Effects of menopausal hormone therapy on the risk of ovarian cancer: Health Insurance Database in South Korea-based cohort study. Menopause. 2023 May 1;30(5):490-496. doi: https://doi.org/10.1097/GME.0000000000002176
Lee HJ, Lee B, Choi H, Kim T, Kim Y, Kim YB. Impact of Hormone Replacement Therapy on Risk of Ovarian Cancer in Postmenopausal Women with De Novo Endometriosis or a History of Endometriosis. Cancers (Basel). 2023 Mar 10;15(6):1708. doi: https://doi.org/10.3390/cancers15061708
Baek C, Kim JE, Shin A, Choi JY. Association of menopausal hormone therapy with gastric and colorectal cancer risks in Korean women: A nationwide population-based cohort study. Maturitas. 2022 Dec;166:35-40. doi: https://doi.org/10.1016/j.maturitas.2022.08.006
Yuk JS, Kim BY. Relationship between Menopausal Hormone Therapy and Oral Cancer: A Cohort Study Based on the Health Insurance Database in South Korea. J Clin Med. 2022 Oct 2;11(19):5848. doi: https://doi.org/10.3390/jcm11195848
Baek JK, Kim HI, Kang MJ, Seon KE, Kim EH, Seo SK. Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea. Climacteric. 2022 Oct;25(5):516-522. doi: https://doi.org/10.1080/13697137.2022.2077096
Lee J, Kim Y, Park H, Kim C, Cho S, Kim J. Clinical Impact of Hormone Replacement Therapy on Atrial Fibrillation in Postmenopausal Women: A Nationwide Cohort Study. J Clin Med. 2021 Nov 24;10(23):5497. doi: https://doi.org/10.3390/jcm10235497
Genazzani AR, Monteleone P, Giannini A, Simoncini T. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. Hum Reprod Update. 2021 Oct 18;27(6):1115-1150. doi: https://doi.org/10.1093/humupd/dmab026
Aguayo-Cerón KA, Gutiérrez-Iglesias G, Parra-Barrera A, Ocharan-Hernández ME, Romero-Nava R, Jiménez-Zamarripa CA, Calzada-Mendoza CC. Antisclerothic effect of tibolone by reducing proinflammatory cytokines expression, ROS production and LDL-ox uptake in THP-1 macrophages. Steroids. 2021 Mar;167:108779. doi: https://doi.org/10.1016/j.steroids.2020.108779
Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JE. Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age. Am J Epidemiol. 2021 Feb 1;190(3):365-375. doi: https://doi.org/10.1093/aje/kwaa210
Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review. Cancers (Basel). 2020 Aug 6;12(8):2195. doi: https://doi.org/10.3390/cancers12082195
Rahkola-Soisalo P, Savolainen-Peltonen H, Gissler M, Hoti F, Vattulainen P, Ylikorkala O, Mikkola TS. Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy. Int Urogynecol J. 2019 Feb;30(2):251-256. doi: https://doi.org/10.1007/s00192-018-3682-7
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J; WHI Investigators. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017 Sep 12;318(10):927-938. doi: https://doi.org/10.1001/jama.2017.11217
Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinoudaki I, Theodorou M, Goulis DG. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. Maturitas. 2017 May;99:27-36. doi: https://doi.org/10.1016/j.maturitas.2017.02.009
Isidoro B, Lope V, Whelan D, Pedraz C, Sánchez-Contador C, Santamariña C, Moreo P, Vidal C, Salas-Trejo D, Ederra M, Aragonés N, Pérez-Gómez B, Pollán M. Use of hormone therapy and isoflavones and mammographic density in Spain. Menopause. 2016 May;23(5):556-64. doi: https://doi.org/10.1097/GME.0000000000000569
Antoine C, Ameye L, Paesmans M, de Azambuja E, Rozenberg S. Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries. Maturitas. 2016 Feb;84:81-8. doi: https://doi.org/10.1016/j.maturitas.2015.11.010
Suhrke P, Zahl PH. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study. Cancer Med. 2015 Aug;4(8):1303-8. doi: https://doi.org/10.1002/cam4.474
Malik R, Meghana Reddy P. Effectiveness of Tibolone in Relieving Postmenopausal Symptoms for a Short-Term Period in Indian Women. J Obstet Gynaecol India. 2023 Jun;73(3):242-247. doi: https://doi.org/10.1007/s13224-022-01727-7
Shyu YK, Pan CH, Liu WM, Hsueh JY, Hsu CS, Tsai PS. Health-related quality of life and healthcare resource utilization in Taiwanese women with menopausal symptoms: a nation-wide survey. J Nurs Res. 2012 Sep;20(3):208-18. doi: https://doi.org/10.1097/jnr.0b013e318265619b
Castrejón-Delgado L, Castelán-Martínez OD, Clark P, Garduño-Espinosa J, Mendoza-Núñez VM, Sánchez-Rodríguez MA. Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis. Biology (Basel). 2021 Mar 10;10(3):211. doi: https://doi.org/10.3390/biology10030211
Na Z, Wei W, Xu Y, Li D, Yin B, Gu W. Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis. Open Life Sci. 2023 Dec 12;18(1):20220759. doi: https://doi.org/10.1515/biol-2022-0759
Zou SB, Zeng ZH. Effects of tibolone combined with zoledronic acid on bone density, bone metabolism, and pain in postmenopausal patients with osteoporosis. Am J Transl Res. 2024 Jul 15;16(7):3395-3404. doi: https://doi.org/10.62347/YDKM2312
Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D'Amico R, Bassi C, Maestri E. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016 Oct 12;10(10):CD008536. doi: https://doi.org/10.1002/14651858.CD008536.pub3
Lee JK, Yun H, Kim H, Yun BH, Seo SK. Tibolone and Breast Cancer. J Menopausal Med. 2023 Dec;29(3):92-96. doi: https://doi.org/10.6118/jmm.23032
Sánchez-Prieto M, et al. The effect of tibolone on female sexual function in postmenopausal women: a systematic review. Maturitas. 2023;173:114. doi: https://doi.org/10.1016/j.maturitas.2023.04.254
Diaby VK, Perreault S, Lachaine J. Economic impact of tibolone compared with continuous-combined hormone replacement therapy in the management of climacteric symptoms in postmenopausal women. Maturitas. 2007;58(2):138-49. doi: https://doi.org/10.1016/j.maturitas.2007.07.004
Marlatt KL, Beyl RA, Redman LM. A qualitative assessment of health behaviors and experiences during menopause: A cross-sectional, observational study. Maturitas. 2018 Oct;116:36-42. doi: https://doi.org/10.1016/j.maturitas.2018.07.014
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 Revista Científica Integrada
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
